Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus virus that can infect both B lymphocytes and epithelial cells. Depending upon the cell type and its state of differentiation, infection by EBV leads to either lytic replication with cell death or a latent infection. Latent EBV infections are associated with several B-cell and epithelial-cell malignancies including Burkitt's lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas in immunocompromised individuals, nasopharyngeal carcinoma, and some gastric carcinomas. Thus, understanding regulation of EBV latency versus lytic replication is crucial for developing therapies to treat these diseases. The BZLF1 and BRLF1 genes of EBV encode multifunctional proteins essential for lytic replication. While the BZLF1 and BRLF1 promoters are inactive in latently infected cells, cell differentiation and activators of certain cell signaling pathways can induce BZLF1 and BRLF1 expression, promoting EBV reactivation into lytic replication. In this Project, we will (i) identify cellular factors that play key roles in regulating expression of these two immediate-early genes in both B cells and epithelial cells, and (ii) examine how these factors contribute to controlling the balance between latent and lytic EBV infection in a variety of cell types and during cellular differentiation. In conjunction with Project 5, these results may lead to new therapies for treating EBV-associated cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA022443-35
Application #
8377341
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
35
Fiscal Year
2012
Total Cost
$310,750
Indirect Cost
$99,331
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Zumwalde, Nicholas A; Sharma, Akshat; Xu, Xuequn et al. (2017) Adoptively transferred V?9V?2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. JCI Insight 2:
Ma, Shi-Dong; Tsai, Ming-Han; Romero-Masters, James C et al. (2017) Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential. J Virol 91:
Bilger, Andrea; Plowshay, Julie; Ma, Shidong et al. (2017) Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication. Oncotarget 8:44266-44280
Yang, Ya-Chun; Liem, Amy; Lambert, Paul F et al. (2017) Dissecting the regulation of EBV's BART miRNAs in carcinomas. Virology 505:148-154
Iwahori, Satoko; UmaƱa, Angie C; VanDeusen, Halena R et al. (2017) Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins. J Biol Chem 292:6583-6599
Wille, Coral K; Li, Yangguang; Rui, Lixin et al. (2017) Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency. J Virol 91:
Chandra, Janin; Kuo, Paula T Y; Hahn, Anne M et al. (2017) Batf3 selectively determines acquisition of CD8+ dendritic cell phenotype and function. Immunol Cell Biol 95:215-223
Pocock, Ginger M; Zimdars, Laraine L; Yuan, Ming et al. (2017) Diverse activities of viral cis-acting RNA regulatory elements revealed using multicolor, long-term, single-cell imaging. Mol Biol Cell 28:476-487
Nowak, Karolin; Linzner, Daniela; Thrasher, Adrian J et al. (2017) Absence of ?-Chain in Keratinocytes Alters Chemokine Secretion, Resulting in Reduced Immune Cell Recruitment. J Invest Dermatol 137:2120-2130
Uberoi, Aayushi; Lambert, Paul F (2017) Rodent Papillomaviruses. Viruses 9:

Showing the most recent 10 out of 420 publications